SUMOylation enhances DNMT1 function to repress mega-intergenic RNAs and viral mimicry - Nature

What the report says

Nature reports that researchers used a selective inhibitor of DNA methyltransferase 1, or DNMT1, to clarify how the enzyme is positioned on chromatin and how its activity is controlled. DNMT1 is a key enzyme for maintaining DNA methylation patterns in mammals, a process important for development and often altered in cancer. The study says DNMT1 is found at unmethylated CpG islands of actively transcribed genes, largely through its CXXC domain, and that catalytic inhibition causes it to move to partially methylated, less accessible regions through mechanisms involving UHRF1 and the RFTS domain.

According to the article preview, blocking DNMT1’s catalytic activity did not substantially change protein-coding gene expression at first. However, prolonged inhibition and broader loss of DNA methylation reactivated endogenous viral elements. The authors describe a previously uncharacterized class of double-stranded RNA mega-intergenic transcripts, called mintRNAs, that can drive a cell-intrinsic “viral mimicry” response, in which cells behave as though they are sensing viral material.

The study identifies RNF4 as a major regulator of DNMT1 catalytic function. Beyond RNF4’s known role in resolving DNA–protein crosslinks, the researchers report that it influences levels of SUMOylated DNMT1. This SUMOylation appears to increase DNMT1 mobility and support DNA methylation, helping repress endogenous retroviral-element-dependent transcripts and limiting viral mimicry.

The findings matter because DNMT1 and DNA hypomethylating drugs are relevant to cancer biology and therapy. Nature’s preview also notes the authors found viral mimicry did not account for cancer cell death caused by DNA hypomethylation, suggesting the relationship between DNMT1 inhibition, immune-like signaling and treatment effects may be more complex than a simple cause-and-effect model.